Reading the offer · 14 company examples
FDA Letters About Clinical and Approval Claims
Whose evidence is behind the advertised result?
A study of an approved branded product does not automatically establish the same result for every compounded preparation described with the molecule’s name. These letters challenge clinical-result language, claims of approval, or both in advertising for compounded medications.
When a higher price is justified by “clinically proven” language, ask which finished product and study support that statement. When a lower price is presented as an equally proven alternative, the same question applies. The company sections identify what FDA actually quoted rather than grading a medication’s safety from an advertising dispute.
Some letters cite only a short phrase; others cite numerical results or a direct approval statement. Those differences matter. This guide preserves them and does not turn an agency warning letter into a trial result or a final court finding.
For an individual example involving repeated letters, read the AM RX record. Its recorded dates distinguish the letter from later company activity.
An FDA warning letter is a public regulatory communication stating the agency's view. It is not a recall, a fine, a criminal charge, an injunction, or a finding that a company has broken the law.
This guide was organized in October 2026. Each company’s source-check date below is kept separately; the guide date does not mean its letter status was checked again.
eDrugstore
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
Where most letters in this round of FDA letters object to an implied equivalence, FDA here quoted claims that state FDA approval directly: "FDA-Approved Active" and "eDrugstore guarantees that all Tirzepatide medications are genuine, FDA-approved formulations for maximum efficacy and safety," together with a product listing reading "Tirzepatide (Zepbound)…." FDA said these claims about the company's compounded tirzepatide imply the products are the same as an FDA-approved product when they are not.
What it means for the offer
Of all the wording FDA quoted across these letters, the phrase used here is the one a price shopper is most likely to be reassured by and least able to check: a guarantee that the medication is a genuine, FDA-approved formulation. A compounded drug is by definition not an FDA-approved drug — that is the structural point, and it does not depend on anything about this seller's quality. The practical takeaway is narrow and useful: an "FDA-approved" badge next to a compounded product's price is not a claim about that product's regulatory status, and FDA said as much in writing here. It is also worth knowing that the letter and the Healthy Male letter issued the same day print the same Tempe, Arizona address, so a shopper comparing the two sites is not necessarily comparing two independent operations.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [eDrugstore's website] in August 2025 and has observed that your website offers various compounded drug products, including tirzepatide.
"FDA-Approved Active"
"eDrugstore guarantees that all Tirzepatide medications are genuine, FDA-approved formulations for maximum efficacy and safety."
"Tirzepatide (Zepbound)…."
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.
eDrugstore's website returned a live storefront when we checked in August 2026, with a weight-loss category listed alongside an extensive erectile-dysfunction catalog and an affiliate sign-in in the site header.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Elite Health Center
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA cited one claim, and it is a history rather than a comparison: "Compounded semaglutide was first introduced and patented in 2016, and FDA approved as a type 2 diabetes treatment in 2017. It wasn’t until 2021 that compounded semaglutide was approved as a treatment for obesity!" The sentence attaches the word "compounded" to both approval dates, so it does not merely imply approval by association — it states outright that the compounded product was approved, twice, on specified dates. FDA's response was the standard one: "Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not."
What it means for the offer
Every other seller on this list leans on a brand name to imply approval. This one skipped the borrowing and simply narrated an approval that never happened, complete with years. That is worth noticing because dates read as research: 2016, 2017, 2021 sound like someone checked. What the dates actually describe is the approval history of Ozempic and Wegovy — brand-name semaglutide made by a manufacturer under an approved application — and the sentence quietly moves the word "compounded" in front of each of them. A compounded drug is prepared for a patient outside that process, which is the whole reason it can be sold at a different price. So the copy was, in effect, charging for the thing that makes compounding cheaper while describing the thing that makes brands expensive. The letter says nothing about the medication's safety or how it was made. The useful follow-up is not "is this approved" but "what exactly am I being sent, and at what dose" — a question that a page willing to invent an approval date is unlikely to answer well. The site no longer runs the cited line, and now states plainly that its medications are compounded and not FDA-approved.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Elite Health Center's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide. As described below, your claim concerning compounded semaglutide products is false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].
The following claim concerning compounded semaglutide products appears on your website:
“Compounded semaglutide was first introduced and patented in 2016, and FDA approved as a type 2 diabetes treatment in 2017. It wasn’t until 2021 that compounded semaglutide was approved as a treatment for obesity!”
Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
Elite Health Center's website was a live store in August 2026, titled "Elite Health Center NJ - Medical Weight Loss, Semaglutide, Lose Weight Fast", running two dated promotions (a $100 first-program discount and a save-$100-plus-free-shipping offer stated as August 3–10) with a working checkout — an operating seller. The cited history does not appear on the page today; the current copy instead carries the line "These medications are compounded and not FDA-approved."
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
EvoLife Wellness
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
The first claim FDA quoted is two words with nothing attached: "FDA-Approved". No product, no application, no indication — a bare badge. The second supplies the missing object but attaches it to the molecule rather than the product: "Clinically Proven: Semaglutide is FDA-approved for chronic weight management…." FDA's answer is one line long and in the same register: "Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not."
What it means for the offer
"FDA-Approved" with nothing after it is the purest version of the problem this collection is about. Every other claim here at least names something — an ingredient, a brand, a comparison you could go and check. This one is a badge, and a badge is designed to be read at a glance and not interrogated. The habit it argues for is a single question with three parts: approved for WHAT, in WHICH form, and under WHOSE application. An approval in the United States attaches to a specific product made by a specific company to a specific formulation and strength, and it is looked up by application number. It does not attach to a molecule, and it cannot be inherited by a different preparation of the same molecule. The second claim shows how the slip happens honestly: semaglutide IS approved for chronic weight management — as Wegovy, made by Novo Nordisk — and a sentence that says so is true right up until it appears on a page selling something else. That is why FDA's reply is so short. It does not dispute the science; it points out which product the approval belongs to. Nothing in this letter concerns how these products were made or what was in them, and it has not been closed out.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [EvoLife Wellness' website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.
The following claims concerning compounded semaglutide and tirzepatide products appear on your website: “FDA-Approved”
“Clinically Proven: Semaglutide is FDA-approved for chronic weight management….”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
EvoLife Wellness' website was live in August 2026, though still carrying the default title of the website builder it was made with ("Lovable App"). Behind that, it carries EvoLife branding, tirzepatide and semaglutide copy and a price ladder running $199 / $299 / $399 / $499 / $599 / $799, which is a trading storefront rather than a placeholder. Recorded as operating on that basis; an unedited page title is a website leftover, not evidence about the business.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
GoodGirlRX
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
No hedge, no comparison: FDA cited the flat statements "FDA-approved meds." and "FDA-approved options", plus "Clinically proven GLP-1 results". Most letters in this round of FDA letters quote a sameness claim that implies approval indirectly; here the site simply asserted it. FDA said the claims imply the products "have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not," and separately noted the pictured label identifies GoodGirlRX as the compounder "when in fact it is not."
What it means for the offer
Most of these letters require you to follow an inference — same ingredient, therefore same product, therefore same approval. This one skips the chain. "FDA-approved meds." is a two-word assertion about regulatory status, and compounded semaglutide and tirzepatide do not have that status, which is why it was cited. That makes this a good page to read first if you are new to the topic, because there is nothing subtle to argue about. It also makes the pricing point simple. A first-month promotional price sitting under the words "FDA-approved" invites you to think you are getting an approved medicine at a discount. You are being offered a compounded preparation at a compounded price. That may still be the right purchase for you — the letter makes no finding about the product or the company's care — but you should make it knowing which of the two things you are buying.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [GoodGirlRX's website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.
“FDA-approved meds.”
“FDA-approved options”
“Clinically proven GLP-1 results”
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
GoodGirlRX's website returned a live storefront when we checked in August 2026, advertising a first-month price and covering weight loss, hormone therapy, anti-aging and wellness for women. We did not review every page on the site.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Healthon
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA cited four claims, and the last one is the interesting one because it is hedged: "The active ingredient in our formula is FDA-approved…." — a sentence that attaches approval to the ingredient rather than to the product. It was cited alongside three blunter lines, "Same active ingredient as Wegovy and Ozempic.", "Same active ingredient as Mounjaro pens and Zepbound." and "Clinically proven weight loss". FDA's conclusion was the same for all four: the claims imply the compounded products are the same as an FDA-approved product when they are not.
What it means for the offer
This is the letter to read if you have ever been reassured by the phrase "FDA-approved active ingredient." It is a real distinction — the molecule genuinely is the one in an approved product — and it is also the single most effective way to make a cheaper vial feel equivalent to a costlier one. FDA cited it because approval attaches to a finished product: a specific formulation, made under a specific application, at a specific strength. The ingredient passing that test tells you nothing about the vial around it. Notice what the letter does not say: it makes no finding about how this company's product was made or whether it works. It is about the sentence, not the syringe. If a price looks lower than a brand's, the honest comparison is compounded-versus-brand, not approved-versus-approved.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Healthon's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.
“Same active ingredient as Wegovy and Ozempic.”
“Clinically proven weight loss”
“The active ingredient in our formula is FDA-approved….”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.
Healthon's website returned a live storefront when we checked in August 2026, offering doctor-led weight-loss plans with an advertised starting price and separate semaglutide and tirzepatide products. We did not review every page on the site.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Healthy Male
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
Rather than the same-ingredient comparison that runs through most of this round of FDA letters, FDA cited a numeric results claim on Healthy Male's website: "Clinically shown to support 15-22% average body weight reduction." It quoted two further claims alongside it — "Clinically proven medications and compounds for sustainable weight management" and "Clinically proven to deliver sustainable results…." — and said these claims about the company's compounded tirzepatide imply the products are the same as an FDA-approved product when they are not.
What it means for the offer
A percentage is the most persuasive thing a weight-loss page can put next to a price, and it is also the easiest thing to borrow. FDA's objection here was not that the 15-22% figure is invented — trial results in that range exist for the approved tirzepatide product — but that presenting it as what this compounded product is "clinically shown" to do implies an evidence base and an FDA review the compounded product has not had. If you are weighing a monthly cost against an expected result, the cost is a fact about the seller and the percentage is a fact about somebody else's clinical trial. This letter is FDA saying the two should not be presented as one.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Healthy Male's website] in August 2025 and has observed that your website offers various compounded drug products, including tirzepatide.
"Clinically shown to support 15-22% average body weight reduction."
"Clinically proven medications and compounds for sustainable weight management" "Clinically proven to deliver sustainable results…."
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.
Healthy Male's website resolved and returned a live storefront when we checked in August 2026, with a weight-loss category still listed among a broad men's-health catalog built mainly around erectile dysfunction and testosterone support.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
iVisitDoc
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
The claim FDA cited is unusual because it admits a difference: "Compounded semaglutide from iVisitDoc has the same active ingredients as Wegovy and Ozempic, but doesn't come in a preloaded pen." FDA's objection was that the difference disclosed is the packaging while the sameness asserted is the drug — compounded products are not FDA-approved, so the claim implies an equivalence that does not exist. The agency also cited the phrase "Clinically Validated Ingredients".
What it means for the offer
A disclosure in the right sentence can make the rest of it more convincing, and that is what happened here. By telling you what you do not get — the preloaded pen — the copy signals candour, and candour makes the sameness claim beside it easier to accept. FDA's objection is that the two halves are about different things: the pen is packaging, the approval is about the finished drug product, and the compounded vial is not the approved one no matter what device it arrives in. "Clinically Validated Ingredients" does the same job more quietly, because validation of an ingredient is not evaluation of a product. For a price comparison the lesson is narrow and useful: when a listing volunteers one difference, that is not a warranty that it has volunteered all of them. Check the form, the concentration and who compounded it before treating a lower number as the same purchase.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [iVisitDoc's website] in August 2025 and has observed that your website offers various compounded semaglutide drug products.
“Compounded semaglutide from iVisitDoc has the same active ingredients as Wegovy and Ozempic, but doesn’t come in a preloaded pen.”
“Clinically Validated Ingredients”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.
In August 2026 iVisitDoc's website still listed weekly injectable semaglutide and tirzepatide and linked a weight-loss intake at iVisitDoc's store site, which was live. We did not complete an intake.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Lyfe Rx
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA quoted the same sentence twice, once per product, with only the drug name changed: "Clinically Proven Weight Loss – Semaglutide has been shown to…." and "Clinically Proven Weight Loss – Tirzepatide has been shown to…." Both quotations break off at the identical point — four words into whatever was meant to support them — because the claim is finished before the evidence starts. FDA's conclusion is the wave's standard one: "Your claims imply that your products are the same as an FDA-approved product when they are not."
What it means for the offer
"Clinically proven" is a phrase with a specific meaning and a specific owner. It means a drug went through controlled trials, that a regulator read them, and that the result is written into an approved label a buyer can go and read. A compounded product has none of that: it is prepared by a pharmacy for an individual patient, it has no approved label, and no trial was run on it. So the sentence borrows a standard that was earned by a different product. What makes this letter worth reading twice is where FDA's quotation stops. It cites the assertion and then the first four words of the sentence underneath — "has been shown to…." — and stops. Shown to do what, in whom, against what comparator, over how long: none of that is in the citation, because none of it was load-bearing. The header did the selling. And because the identical header ran on both product pages with only the molecule changed, it was never a statement about semaglutide or about tirzepatide; it was furniture. That is the practical test for a shopper: read the proof sentence, not the proof headline, and see whether it names a study you could look up. Checked on 2026-08-09, that language is gone from both product pages FDA named — "clinically" now appears on them only in the sense of "clinically appropriate" and "clinically authorized", describing when a provider will approve an order rather than what the drug will do. The site is trading normally at published prices. The letter concerns wording, makes no finding about how the products were made or what is in them, and FDA has not closed it out.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Lyfe Rx's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.
The following claims concerning compounded semaglutide and tirzepatide products appear on your website:
• “Clinically Proven Weight Loss – Semaglutide has been shown to….” • “Clinically Proven Weight Loss – Tirzepatide has been shown to….”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
Lyfe Rx's website was a live storefront in August 2026, titled "Lyfe RX | Wellness & Weight Loss Delivered to Your Door!", with published prices on the two products the letter names (semaglutide $225.00, tirzepatide $299.00), six further protocols, a working cart, and a comparison table the site itself dates "as of August 2026". This is a check of whether the site is up and what it sells; it is not a check of anything the letter alleges.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Mane & Steel
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA quoted two claims, neither of which names a brand-name drug or uses the word "FDA": "Clinically Proven Weight Loss" and "Clinically proven GLP-1 therapy to suppress appetite, regulate blood sugar, and accelerate fat loss—trusted by medical professionals worldwide." Its conclusion is the same one it reaches in letters quoting explicit brand comparisons — "Your claims imply that your products are the same as an FDA-approved product when they are not" — so the finding rests on the phrase "clinically proven" alone rather than on any reference to an approved product.
What it means for the offer
This is the letter to read if you have concluded that the problem in this market is brand-name comparisons. There is no brand here. Neither quoted line mentions Ozempic or Wegovy, neither says "FDA", and neither claims equivalence to anything — they say "clinically proven" and "trusted by medical professionals worldwide". FDA reached the same conclusion it reaches against pages that do name brands. The reason is that clinical proof is what approval represents; a page claiming the proof is claiming the substance of approval without the word. For anyone comparing offers, that is the more useful test. Scanning marketing copy for brand names and "FDA-approved" badges will miss the version of the claim that skips both, and "clinically proven" is doing exactly the same work on the reader. The letter makes no statement about whether the medication is safe or whether it works — only that the trials implied by "proven" were not run on the compounded product being sold.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Mane & Steel's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide. As described below, your claims concerning compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].
The following claims concerning compounded semaglutide products appear on your website: • “Clinically Proven Weight Loss” • “Clinically proven GLP-1 therapy to suppress appetite, regulate blood sugar, and accelerate fat loss—trusted by medical professionals worldwide.”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
Mane & Steel's website was live in August 2026, titled "MANE & STEEL | Hair Loss Prevention For Men", selling prescription dutasteride hair-loss protocols with account creation. The compounded semaglutide line the letter concerns was not visible on the homepage, which mentioned dutasteride 83 times and semaglutide, GLP-1 and weight loss not at all. The company is operating; the product the letter is about was not on display.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Maxlife
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
Alongside the pictured-label finding — the products "identify “Maxlife” on the pictured label, suggesting Maxlife is the compounder of those drugs when in fact it is not" — FDA quoted six claims from the site, two of which state approval directly rather than by implication: "With the same active ingredient as Wegovy® and Ozempic®, this treatment has been clinically tested and FDA-approved for effective weight management." and the same sentence for Mounjaro® and Zepbound®. A standalone "FDA Approved" appears in the quoted list as well, together with "generic compounded medication" and two further lines reading "Active ingredients in Ozempic® & Wegovy®" and "Active ingredients in Mounjaro® & Zepbound®". FDA's answer is one flat sentence: "Compounded drug products are not FDA-approved."
What it means for the offer
Most letters in this collection are an argument about inference: a page says two products share an active ingredient, FDA says a reader will take that to mean the compounded one has been approved, and the copy is misleading for that reason. This one skips the argument. The page said "clinically tested and FDA-approved for effective weight management" and carried an "FDA Approved" badge, and FDA's reply is a single sentence with nothing to interpret: compounded drug products are not FDA-approved. That distinction matters when you are deciding how much weight to give any one letter. An inference can be argued about; a direct claim of approval either matches the record or it does not, and this one did not. The practical consequence is narrow and specific. "FDA-approved" next to a monthly price is the single strongest reason a shopper has to stop comparing and buy, because it appears to end the question of whether the product works. It did not end that question here, and the letter says so without saying anything at all about whether the medication is safe or what it should cost.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Maxlife's website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.
The compounded semaglutide and tirzepatide products displayed on your website identify “Maxlife” on the pictured label, suggesting Maxlife is the compounder of those drugs when in fact it is not.
Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website: “generic compounded medication” “With the same active ingredient as Wegovy® and Ozempic®, this treatment has been clinically tested and FDA-approved for effective weight management.” “With the same active ingredient as Mounjaro® and Zepbound®, this treatment has been clinically tested and FDA-approved for effective weight management.” “FDA Approved” “Active ingredients in Ozempic® & Wegovy®” “Active ingredients in Mounjaro® & Zepbound®”
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
Maxlife's website returned a live site on 2026-08-09 titled "GLP-1 Weight Loss Program Online | MaxLife", advertising semaglutide and tirzepatide programs "Starting at $155/mo" with a get-started flow and free expedited shipping.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Peaks
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA quoted copy from Peaks' website describing a compounded semaglutide product as "This FDA-approved treatment promotes safe, effective weight loss, helping you reduce up to 20% of your body weight and maintain long-term results," alongside "Clinically proven to aid in significant weight loss in overweight adults," "Safe, affordable, and effective," and "The compounded products offered on [Peaks' website] use FDA approved active pharmaceutical ingredients (API)." FDA also found that the pictured labels identify "Peak Now" as the compounder when it is not, and concluded the claims imply the products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
What it means for the offer
One of the four claims here is more technical than the rest and deserves separating out, because it is the version a well-informed shopper is most likely to accept: the products "use FDA approved active pharmaceutical ingredients (API)". Approval in the FDA sense attaches to a finished drug product, not to an ingredient in isolation, so an API-level approval claim describes something that does not exist in the form the sentence implies. Around it sit the three claims that need no unpicking at all — FDA-approved treatment, clinically proven, safe. The most useful thing to take from this letter is that the sophistication of a claim is no guide to its accuracy, and that "affordable" was the one word in "safe, affordable, and effective" FDA had no argument with.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Peaks' website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide drug products.
The compounded semaglutide products displayed on your website identify “Peak Now” on the pictured label, suggesting Peak Now is the compounder of those drugs when in fact it is not.
“This FDA-approved treatment promotes safe, effective weight loss, helping you reduce up to 20% of your body weight and maintain long-term results.”
“Clinically proven to aid in significant weight loss in overweight adults.” “Safe, affordable, and effective.” “The compounded products offered on [Peaks' website] use FDA approved active pharmaceutical ingredients (API).”
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
Peaks' website returned a live storefront when we checked in August 2026, still selling a weight-loss line among a wider sexual-health and wellness catalog. Neither semaglutide nor the Peak Now name appeared on the homepage at that check, though we did not review the whole site.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Slendid
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA quoted a single four-word phrase from the site — "Clinically proven weight loss treatments" — and nothing else. The agency's objection was that "clinically proven" implies the compounded product is the same as an FDA-approved one, when compounded drugs are not FDA-approved. No price, no dosing claim and no safety claim appears anywhere in FDA's list.
What it means for the offer
Four words drew this letter, which is the most useful thing about it. "Clinically proven" is doing a specific job in a price comparison: it invites you to treat a cheaper compounded vial and an approved brand as interchangeable, so that the only remaining difference is the number. FDA's point is that the trials behind that phrase were run on the approved product, not on the compounded one you would be buying. That does not mean the medication does not work or that the company misled anyone deliberately — it means the phrase carries more authority than the product behind it has earned. Read the price for what it is, and read "clinically proven" as marketing copy rather than a regulatory status.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Slendid's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.
The following claim concerning compounded semaglutide and tirzepatide products appears on your website:
“Clinically proven weight loss treatments”
Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not.
Slendid's website returned a live storefront when we checked in August 2026, still selling online GLP-1 prescriptions with a client portal and a published phone number. We did not review every page on the site.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
TRYM Health
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA cited three claims from TRYM Health's website: a flat four-word efficacy line, "Clinically Proven to Work," and two ingredient comparisons, "Contains the same active ingredient as Mounjaro and ZepBound [sic]." and "Contains the same active ingredient as Ozempic and Wegovy." The bracketed "[sic]" is FDA's own, marking a spelling in the company's copy. FDA concluded the claims imply the compounded semaglutide and tirzepatide products are the same as an FDA-approved product when they are not.
What it means for the offer
"Clinically Proven to Work" is four words with no product, no trial and no number attached to it, and that is precisely what FDA objected to: a claim that broad, sitting above a compounded product, borrows the evidence base of the approved drugs named further down the page. For a reader comparing subscription prices, the letter changes nothing about what TRYM charges or whether the plan is what it says it is. What it gives you is a way to grade the copy around the price — an unattached "clinically proven" is a claim about nothing in particular, and the specific comparison underneath it is the claim FDA said goes too far.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [TRYM Health's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.
"Clinically Proven to Work"
"Contains the same active ingredient as Mounjaro and ZepBound [sic]."
"Contains the same active ingredient as Ozempic and Wegovy."
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.
TRYM Health's website returned a live storefront when we checked in August 2026, still selling weight-loss, fitness and healthy-aging plans, and carrying a dated site notice from June 2026 about its email and support systems — evidence of an actively maintained operation rather than a parked domain.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Villas Health
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA quoted two claims covering two different drugs. The semaglutide line is the standard equivalence comparison — "Semaglutide GLP-1 is a once-a-week injection that contains the same active ingredient as Ozempic and Wegovy…." The sildenafil line asserts a proven clinical result instead: "Sildenafil 2%: the active ingredient in Viagra. Clinically proven to improve outcomes in women with sexual arousal disorder by increasing blood flow to the genitals." FDA’s conclusion covers both together — "Your claims imply that your products are the same as an FDA-approved product when they are not."
What it means for the offer
This letter is useful because it shows the same sales technique applied to two very different products, and the second one travels further than the first. Saying compounded semaglutide has the same active ingredient as Ozempic is a chemistry claim that leans on a brand's reputation. Saying a compounded sildenafil product is "clinically proven to improve outcomes in women with sexual arousal disorder" borrows the credibility of Viagra and then attaches it to a use and a population Viagra was never approved for. The word doing the work is "proven", and it is the one the letter disputes. If you are pricing a sexual-health product, that is the practical takeaway: a compounded formulation can share an ingredient with a famous drug and still be sold for something that drug was never shown to do. FDA is not saying either product is dangerous. It is saying that the strength of the evidence implied by "clinically proven" belonged to a different product, and that a shopper reading the page would not have known which.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Villas Health's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and sildenafil. As described below, your claims concerning compounded semaglutide and sildenafil products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].
The following claims concerning compounded semaglutide and sildenafil products appear on your website: • “Semaglutide GLP-1 is a once-a-week injection that contains the same active ingredient as Ozempic and Wegovy….” • “Sildenafil 2%: the active ingredient in Viagra. Clinically proven to improve outcomes in women with sexual arousal disorder by increasing blood flow to the genitals.”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
Villas Health's website returned a live site on 2026-08-09 headed "Home Page - Villas Health" with a working catalog running a promotional code, listing Compounded GLP-1 "begins from $179 your First Month" and Sildenafil "begins from $60.00"-tier products among a wider sexual-health range — both of the product lines the letter names are still sold.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.